U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: Iron Isomaltoside 1000 (Monoferric): (Pharmacosmos A/S): Indication: For the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 May.

Cover of Pharmacoeconomic Review Report: Iron Isomaltoside 1000 (Monoferric)

Pharmacoeconomic Review Report: Iron Isomaltoside 1000 (Monoferric): (Pharmacosmos A/S): Indication: For the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy [Internet].

Show details

Table 12Ganzoni Formula for Iron Isomaltoside 1000 Dosing

DescriptionResult
Ganzoni formulaIron need (mg iron) = body weight (kg)a × (target Hbb – actual Hb) × 2.4c + depot iron need (mg iron)d
Example patient

50 kg patient

Actual Hb = 11

10 mg/kg assumption for iron stores

Iron need = 50 × (15 – 11) × 2.4 + (10 × 50)

Iron need = 980 mg

70 kg patient

Actual Hb = 9

1,000 mg assumption for iron stores

Iron need = 70 × (15 – 9) × 2.4 + 1,000

Iron need = 2,008 mg

90 kg patient

Actual Hb =10

1,000 mg/kg assumption for iron stores

Iron need = 90 × (15 – 10) × 2.4 + 1,000

Iron need = 2,080 mg

BMI = body mass index; Hb = hemoglobin.

a

Ideal body weight should be used for obese patients, e.g., by calculating weight at BMI.

b

Default target Hb is 15 g/dL. Lower Hb targets may be appropriate based on clinical judgment.

c

2.4 = 0.0034 × 0.07 × 10,000, where 0.0034 is the iron content of Hb, 0.07 is blood volume based on 7% of body weight, and 10,000 is the conversion factor from g/dL to mg/L.

d

For patients above 35 kg, iron stores are at least 500 mg, the lower limit of normal for small women. Some guidelines use 10 mg to 15 mg iron/kg body weight while others use 1,000 mg iron for stores.

From: Appendix 5, Reviewer Worksheets

Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

  • Cite this Page
  • PDF version of this title (520K)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...